Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24721914 | 0.86 | KIF11 (0.38) | ARCES2FFAR1FFAR4PDE2A | |
| SCHEMBL21132233 | 0.79 | PDE2A (0.34) | ARCES2FFAR1FFAR4PDE2A | |
| SCHEMBL15362777 | 0.79 | KIF11 (0.46) | ARCES2FFAR1FFAR4PDE2A | |
| SCHEMBL8225339 | 0.79 | CES2 (0.48) | ARCES2PDE2AKIF11 | |
| SCHEMBL26827647 | 0.79 | AR (0.39) | ARCES2PDE2A | |
| SCHEMBL24722134 | 0.75 | CNR2 (0.41) | — | |
| SCHEMBL19170782 | 0.73 | KIF11 (0.47) | CES2PDE2AKIF11 | |
| SCHEMBL13171669 | 0.73 | KIF11 (0.47) | ARCES2FFAR1FFAR4PDE2A | |
| SCHEMBL21534433 | 0.71 | KIF11 (0.40) | ARCES2PDE2AKIF11 | |
| SCHEMBL12773797 | 0.71 | KIF11 (0.46) | ARCES2FFAR1FFAR4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | AR 716/4885CES2 363/4885FFAR1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.